| EPB0147 | Efficacy and safety of different regimens in the treatment of HIV patients with latent tuberculosis infection: a systematic review and network meta-analysis of randomized controlled trials | E-poster | Co-infections (including opportunistic infections) |
| EPB0146 | Clinical characteristics and outcome of toxoplasma encephalitis in HIV patients from Indonesian tertiary referral hospital | E-poster | Co-infections (including opportunistic infections) |
| EPB0145 | The epidemiological profile of mpox cases in Rio de Janeiro, Brazil: changes over time during the 2022 outbreak | E-poster | Co-infections (including opportunistic infections) |
| EPB0144 | Differences in time to HCV treatment initiation following HCV diagnosis in the broad direct-acting antiviral era in five countries | E-poster | Co-infections (including opportunistic infections) |
| EPB0143 | Cryptococcal antigen (CrAg) screening a need of the hour for PLHIV of Eastern India | E-poster | Co-infections (including opportunistic infections) |
| EPB0142 | High prevalence of asymptomatic Sexually Transmitted Infections in men patients living with HIV | E-poster | Co-infections (including opportunistic infections) |
| EPB0141 | Prevalence and associated risk factors of hepatotoxicity on tuberculosis prevention therapy in a Thai HIV cohort | E-poster | Co-infections (including opportunistic infections) |
| EPB0140 | High prevalence of latent tuberculosis infection among people living with HIV in Thailand, 2022 | E-poster | Co-infections (including opportunistic infections) |
| EPB0139 | Association between high-risk human papillomavirus infections and cervical cytology results among women living with HIV in Kenya | E-poster | Co-infections (including opportunistic infections) |
| EPB0138 | One-dose versus accelerated two-dose schedule for booster HAV vaccination among people living with HIV after primary HAV vaccination | E-poster | Co-infections (including opportunistic infections) |